Zyban

Zyban is a brand name of bupropion, approved by the FDA in the following formulation(s):

ZYBAN (bupropion hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: May 14, 1997
  
  Strength(s): 150MG ^[RLD][AB2]

Has a generic version of Zyban been approved?

A generic version of Zyban has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zyban and have been approved by the FDA:

bupropion hydrochloride tablet, extended release; oral

• 
  Manufacturer: ACTAVIS
  
  Approval date: March 12, 2008
  
  Strength(s): 150MG ^[AB2]


• 
  Manufacturer: ANCHEN PHARMS
  
  Approval date: June 9, 2011
  
  Strength(s): 150MG ^[AB2]


• 
  Manufacturer: IMPAX LABS
  
  Approval date: May 27, 2004
  
  Strength(s): 150MG ^[AB2]


• 
  Manufacturer: MYLAN
  
  Approval date: May 3, 2010
  
  Strength(s): 150MG ^[AB2]


• 
  Manufacturer: WATSON LABS FLORIDA
  
  Approval date: March 24, 2009
  
  Strength(s): 150MG ^[AB2]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zyban. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
  Patent 5,358,970
  Issued: October 25, 1994
  Inventor(s): Ruff; Michael D. & Kalidindi; Sanyasi R. & Sutton, Jr.; Joel E.
  Assignee(s): Burroughs Wellcome Co.
  This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  



• 
  Controlled sustained release tablets containing bupropion
  Patent 5,427,798
  Issued: June 27, 1995
  Inventor(s): Ludwig; Jennie Sue G. & Bass, Jr.; William L. & Sutton, Jr.; Joel E.
  Assignee(s): Burroughs Wellcome Co.
  A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion hydrochloride release in the body.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  



• 
  Stabilized pharmaceutical composition containing bupropion
  Patent 5,731,000
  Issued: March 24, 1998
  Inventor(s): Ruff; Michael David & Kalidindi; Sanyasi Raju & Sutton, Jr.; Joel Elmore
  Assignee(s): Glaxo Wellcome Inc.
  This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  



• 
  Stabilized pharmaceutical
  Patent 5,763,493
  Issued: June 9, 1998
  Inventor(s): Ruff; Michael D. & Kalidindi; Sanvasi R. & Sutton, Jr.; Joel Elmore
  Assignee(s): Glaxo Wellcome Inc.
  This application discloses a method of inhibiting degradation of the antidepressant bupropion hydrochloride in a solid pharmaceutical formulation, so that the pharmaceutical formulation will maintain at least 80% of its initial bupropion potency after one year.
  
  Patent expiration dates:
  
  
  • August 12, 2013
    
  
  

See also...

• Zyban Consumer Information (Drugs.com)
• Zyban Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Zyban Consumer Information (Cerner Multum)
• Zyban Advantage Pack Consumer Information (Cerner Multum)
• Zyban Advanced Consumer Information (Micromedex)
• Bupropion Consumer Information (Drugs.com)
• Bupropion Consumer Information (Wolters Kluwer)
• Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Consumer Information (Cerner Multum)
• Bupropion Advanced Consumer Information (Micromedex)
• Bupropion Hydrochloride AHFS DI Monographs (ASHP)